miR-134 in Extracellular Vesicles Reduces Triple-Negative Breast Cancer Aggression and Increases Drug Sensitivity

Oncotarget - United States
doi 10.18632/oncotarget.5192
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

miR-200–containing Extracellular Vesicles Promote Breast Cancer Cell Metastasis

Journal of Clinical Investigation
Medicine
2014English

Triple-Negative Breast Cancer

2018English

ISL1 Promotes Cancer Progression and Inhibits Cisplatin Sensitivity in Triple-Negative Breast Cancer Cells

International Journal of Molecular Medicine
MedicineGenetics
2018English

Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2015English

DNA Methyltransferase Expression in Triple-Negative Breast Cancer Predicts Sensitivity to Decitabine

Journal of Clinical Investigation
Medicine
2018English

Curcumin Restores Sensitivity to Retinoic Acid in Triple Negative Breast Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

MiR-34b Is Associated With Clinical Outcome in Triple-Negative Breast Cancer Patients

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2012English

lincRNA-RoR and miR-145 Regulate Invasion in Triple-Negative Breast Cancer via Targeting ARF6

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy